Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
MRNA / LNP / RESEARCH LIBRARY
Important mRNA/LNP publications from the past 120 days
Search bilingual publication guides on delivery, in vivo CAR-T, therapeutic translation, safety, analytics, and manufacturing.
BioNTech inaugurated its clinical-scale mRNA manufacturing and R&D facility at La Trobe University’s Bundoora campus in Melbourne. Built around modular BioNTainer technology, the site combines drug-substance production, formulation, and aseptic filling, with subsidized access planned for researchers and start-ups. GMP operational readiness is expected in mid-to-late 2027 after successful commissioning; inauguration does not mean GMP operations have already begun.
A minireview distinguishes bulk encapsulation efficiency from particle occupancy and RNA copy-number distributions. High encapsulation efficiency can coexist with RNA-negative particles, and process changes may alter loading without changing average size. The author cautions that eliminating empty particles does not necessarily improve activity; product-specific evidence must establish whether occupancy is a critical quality attribute.
Acuitas summarized World Vaccine Congress Europe data showing enhanced mRNA vaccine immune responses with ALC-315 in animal tumor models, alongside improved potency of newer lipids in an influenza vaccine model. The release describes preclinical tumor, survival, and immune-response findings. These results should not be read as demonstrated clinical efficacy or a human safety advantage.
A mouse study compared LNP-delivered self-amplifying RNA and an Ad5 vaccine encoding the same RSV prefusion F antigen. Intramuscular dosing produced distinct immune patterns: saRNA favored pulmonary mucosal and tissue-resident memory responses, while Ad5 generated stronger systemic responses. The comparison concerns immune architecture, not demonstrated superiority in human protection.
Researchers separated the effects of circular structure, preparation quality, and nucleotide modification across two vaccine antigen systems. Cleaner circular RNA preparations caused less innate immune activation, but antibody and T-cell response levels were comparable with linear mRNA. Incorporating m6A was associated with higher antibody avidity, rather than a general increase in expression.
Researchers screened PEG-free hybrid particles containing a polylactic acid core and engineered lipid surface. A lead formulation preserved particle size and reporter activity after vibrating-mesh nebulization, outperforming the tested SM-102 reference under those conditions. Non-nebulized particles also transfected organoids and primary airway cultures. The authors identify mucus transport, aerosol deposition, and in vivo efficacy as unresolved next steps.
Serial blood samples from 73 vaccine recipients were analyzed using ddPCR for total and long-range-linked mRNA and LC-MS for ionizable lipids. RNA and lipid decay differed across three vaccine platforms. Cohorts differed in dose, vaccination history, and sampling schedules. Detecting circulating RNA fragments does not by itself establish continued protein expression, clinical toxicity, or comparative vaccine effectiveness.
The CAPSULIX consortium of OZ Biosciences, ExploRNA, and Miltenyi received Eurostars support for a three-year project with a total budget of €1,518,766. It will combine novel cap-analog mRNA or self-amplifying RNA with biodegradable LNPs for nonviral CAR-T manufacturing. GMP-compatible process development and preclinical validation are objectives. The total project budget is not necessarily the amount of grant funding.
BioNTech reported that AHEAD-MERIT, a Phase 2/3 trial of BNT113 plus pembrolizumab, did not meet its progression-free survival dual primary endpoint versus pembrolizumab alone. The study enrolled patients with previously untreated, unresectable recurrent or metastatic HPV16-positive, PD-L1-expressing head and neck cancer. Overall-survival follow-up continues; under the prespecified design, a significant survival benefit could still establish a positive trial outcome.
This repeat-dosing study examined whether changes in PEG chemistry, PEG concentration, RNA cargo, or administration route could overcome efficacy loss after an immunogenic nanoparticle dose. None reliably restored delivery in the tested setting, and reduced activity tracked anti-PEG antibodies. The results emphasize the interaction between ionizable lipids and innate immunity, without establishing that every PEG-containing product will behave identically.
Researchers combined a 520-member degradable lipid library with interpretable machine learning and a 10,920-member virtual design space. Independent mouse experiments identified PA97MD101 as a lead for hepatic mRNA expression, Cre-mediated recombination, and Cas9-based TTR suppression. The study links screening predictions with functional animal validation, without establishing clinical safety or efficacy.
RinuaGene announced an October 4 collaboration framework with the Medicines Patent Pool to explore development, potential licensing, technology transfer, and local manufacturing of investigational therapeutic mRNA candidate RG002 in selected low- and middle-income countries. Other mRNA candidates may also be assessed. This is an exploratory framework, not a completed license, completed technology transfer, or WHO endorsement of an approved product.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
